for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Harbin Pharmaceutical Group Co., Ltd.

600664.SS

Latest Trade

3.37CNY

Change

-0.01(-0.30%)

Volume

8,617,721

Today's Range

3.35

 - 

3.42

52 Week Range

3.00

 - 

6.53

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3.38
Open
3.38
Volume
8,617,721
3M AVG Volume
619.78
Today's High
3.42
Today's Low
3.35
52 Week High
6.53
52 Week Low
3.00
Shares Out (MIL)
2,507.02
Market Cap (MIL)
8,448.65
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Harbin Pharmaceutical Group Co Ltd Earnings Release

Latest Developments

More

Harbin Pharmaceutical Clarifies Media Reports Related To GNC's Restructuring

Harbin Pharmaceutical Swings To H1 Net Loss At 42.3 Million Yuan

Harbin Pharmaceutical Group's Controlling Shareholder To Sell Stake In The Company

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Harbin Pharmaceutical Group Co., Ltd.

HARBIN PHARMACEUTICAL GROUP CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's major products include chemical raw medicines, antibiotics, Chinese medicines, chemical drugs, over-the-counter (OTC) medicines, healthcare products, biological engineering, animal vaccines and animal remedies, including injections, powder injections, oral liquid, tablets and capsules, among others. The Company distributes its products within domestic markets and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No. 7 Qunli Avenue, Daoli District

HAERBIN, HNG

150070

China

+86.451.51870077

http://www.hayao.com

Executive Leadership

Zhenping Zhang

Chairman of the Board

Bo Liu

Chief Accounting Officer, Director

Haiying Xu

General Manager

Zhijun Wu

Deputy General Manager, Director

Bangmin Liu

Deputy General Manager

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
0.76
Price To Book (MRQ)
1.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
64.95
LT Debt To Equity (MRQ)
0.84
Return on Investment (TTM)
-3.54
Return on Equity (TTM)
-1.66

Latest News

Latest News

U.S. senator asks for CFIUS review of GNC purchase by Chinese company

U.S. Senator Marco Rubio, a Republican and a China hawk, asked for a national security review of plans by General Nutrition Centers <GNC.N>, or GNC, to sell itself to Harbin Pharmaceutical Group Co Ltd.

US senator asks for CFIUS review of GNC purchase by Chinese company

U.S. Senator Marco Rubio, a Republican and a China hawk, asked for a national security review of plans by General Nutrition Centers, or GNC, to sell itself to Harbin Pharmaceutical Group Co Ltd.

REFILE-BRIEF-Harbin Pharmaceutical Signs Agreement With Israel's Teva Pharmaceutical Industries

* SAYS IT SIGNS AUTHORIZATION AND DISTRIBUTION AGREEMENT WITH ISRAEL'S TEVA PHARMACEUTICAL INDUSTRIES, EXPECTS INVESTMENT OF ABOUT 160 MILLION YUAN Source text in Chinese: https://bit.ly/2PdGwJL Further company coverage: (Reporting by Hong Kong newsroom)

China's Harbin Pharma to buy stake in U.S. health retailer GNC

China's state-controlled drugmaker Harbin Pharmaceutical Group Holding Co <600664.SS> will buy an about 40 percent stake in U.S. nutritional supplements retailer GNC Holdings Inc <GNC.N> for $300 million and are in talks for a joint venture in China, the companies said.

BRIEF-GNC Holdings Says On Deal Termination Co to Pay Termination Fee Of Either $10 Mln Or $18 Mln To Harbin Pharmaceutical

* GNC HOLDINGS - ON DEAL TERMINATION UNDER CIRCUMSTANCES, CO WILL PAY FEE OF EITHER $10 MILLION OR $18 MILLION TO HARBIN PHARMACEUTICAL GROUP - SEC FILING Source text: (http://bit.ly/2o4g6KY) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up